Results per Page:
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch
Substituting cyclophosphamide for a standard post-transplant immunosuppressant is a “gamechanger”
Surprising findings about blood cell mutations bode well for transplant recipients
Fred Hutch researchers compared blood samples from 16 recipient-donor pairs, some more than 45 years after transplant
Fred Hutch receives funding to advance Indigenous cancer health equity
Cooperative agreement will support work on smoking cessation, lung cancer screening, patient navigation and more
Fred Hutch Phase 1 Program director, Dr. John Thompson, retires
An immunotherapy champion, Thompson co-led the melanoma clinic for decades
Employee-engagement survey delivers welcome news
Fred Hutch employees report they feel valued, including on DEI issues
For Fred Hutch biostatisticians, numbers are no game
Meticulous work at the SWOG Statistics and Data Management Center, housed at Fred Hutch, may alter care for bladder cancer and lymphoma
Fred Hutch Science Education Partnership receives $1.35M grant
The award will support new programming for students and teachers on health inequities
Volunteer patient advocate can’t help helping others
For this podcaster, breast cancer patient and self-described “clinical trials fanatic,” advocacy starts with community building
$5.25M from the Kuni Foundation propels innovative adult oncology research
Grants will support research on tumor regression, immunotherapy access and better care for breast, liver and peritoneal malignancies
10 Washington groups take on cancer health disparities with grants from Fred Hutch
Community Grants Program funds projects statewide to improve cancer outcomes and build organizational capacity
Novel chemoimmunotherapy approach shows promise for B-cell acute lymphoblastic leukemia in phase 1 study at Fred Hutch
DA-EPOCH plus inotuzumab ozogamicin was “safe and highly active” in adults with relapsed or refractory disease
Dr. Bart Scott named Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair
Chair recognizes a quarter-century of commitment to advancing MDS treatment and the opportunities ahead
‘If you want to go far, go together’
Fred Hutch scientist Dr. Jennifer Adair partners with colleagues around the globe to make gene therapies more effective and more widely available
Multiple myeloma research to be presented at American Society of Hematology annual meeting
Dr. Rahul Banerjee to share insights on reducing financial toxicity, time toxicity and side effects of treatment
Dr. Lawrence Fong to lead Immunotherapy Integrated Research Center
International expert will help scale up Fred Hutch’s clinical expertise in solid tumor immunotherapy
Dr. Hans-Peter Kiem awarded amfAR grant for research on HIV gene therapy
Potential cure builds on unexpected findings about hematopoietic stem cells
Grants for community-driven projects help make health equity a reality in Washington
Nine organizations receive support from the Community Grants Program to improve outcomes for underrepresented residents
Dr. Philip Greenberg elected to National Academy of Sciences
Fred Hutch expert in immunology has led development of T-cell therapies for cancer
Six researchers receive $3.5 million in grants from Kuni Foundation
Funds will support innovative high-risk/high-reward projects across Fred Hutchinson Cancer Center/University of Washington/Seattle Children’s Cancer Consortium with the potential to revolutionize care